KCRS24 Program

Program is in development at this time and subject to change.

All times are in EDT

Thursday, July 11th

Registration and Continental Breakfast

RCC Perioperative Trial Collaborative (RCC-PTC)
CLOSED SESSION – Invitation only for Collaborative Members

Moderated by
Axel Bex, Royal Free London Hospital & Grant Stewart, University of Cambridge

KCRS24 Welcome
Bryan Lewis, KidneyCAN President

How the Air We Breathe Can Impact Cancer
Keynote
Charles Swanton, The Francis Crick Institute

Session 1: Exploring Novel Drug Targets for RCC
Moderated by
Pavlos Msaouel, MD Anderson Cancer Center &
Scott Tykodi, Fred Hutchinson Cancer Center

Purinergic Receptor Antagonist Therapeutics in Treating Metastatic Renal Cancer
Jean Jiang, University of Texas Health San Antonio

Identification of Novel Therapeutic Strategies for Chromophobe RCC
Elizabeth Henske, Brigham & Women’s Hospital/Harvard Medical School

Interrogating the Therapeutic Relevance of Targeting The Antiapoptotic BCL-XL Protein in Kidney Cancer
Abhishek Chakraborty, Cleveland Clinic Foundation

SETD2 Deficiency is a Therapeutic Target to Upregulate Viral Mimicry in Treating Aggressive Clear Cell Renal Cell Carcinoma Patients
Gangning Liang, University of Southern California

 

Lunch and Networking
Lunch and Networking
Lunch and Networking

Session 2: Novel Imaging and Biomarkers to Guide RCC Patient
Moderated by
Eric Jonasch, MD Anderson Cancer Center &
Katy Beckermann, Vanderbilt University Medical Center

PET Imaging of HIF-2a in Renal Cancer
Xiankai Sun, University of Texas Southwestern Medical Center

Multiplexed Quantification of Urinary Biomarkers for Noninvasive Classification of Imaged Kidney Tumors
Jeremiah Morrissey, Washington University in St. Louis

Multimodal AI-Based Renal Cancer Patient Care
Christopher Weight, Cleveland Clinic Foundation

Shared Heritability Between Renal Cell Carcinoma and Hematopoietic-Related Phenotype
Valisha Shah, Dana-Farber Cancer Institute

Session 3: State of the Science
Moderated by
Rohit Mehra, University of Michigan &
Payal Kapur, University of Texas Southwestern Medical Center

Taxonomic Evolution of Kidney Cancer with Emphasis on Molecularly Defined RCC
Samson Fine, Memorial Sloan Kettering Cancer Center

Surgical Pathology Toolbox and Technological Advances to Solve Kidney Cancer Problems
Michelle Hirsch, Brigham & Women’s Hospital

Prognostic and Predictive Biomarkers in Kidney Cancer
Payal Kapur, University of Texas Southwestern Medical Center

Sarcomatoid Renal Cell Carcinoma: Diagnostic Updates and Therapeutic Implications
Sabina Signoretti, Brigham and Women’s Hospital

Role of Pathologist in Kidney Cancer Diagnostics and Research
Rohit Mehra, University of Michigan

 

Afternoon Break

Session 4: Trials in Progress
Moderated by
Robert Motzer, Memorial Sloan Kettering Cancer Center &
Naomi Haas, Abramson Cancer Center/University of Pennsylvania

SPEAKERS TO BE DETERMINED

Awards Announcement and Closing
• AACR – KidneyCAN Innovation and Discovery Grants
• KCRS24 Abstract Merit Awards
Bryan Lewis, KidneyCAN President

Posters and Prosecco

Reception – Smith & Wollensky

Friday, July 12th

Rock the Run 5K

Registration and Breakfast
KCRS24 Welcome
Bryan Lewis, KidneyCAN President

Metabolism and Immunotherapy
Featured Speaker
Jeffrey Rathmell, Vanderbilt University Medical Center

Session 5: Clinical and Scientific Updates in Kidney Cancer
Moderated by
Toni Choueiri, Dana-Farber Cancer Institute

Front Line Systemic Therapy Strategies
Tom Powles, Barts Cancer Centre

Subsequent Line Treatments for Advanced Disease
Robert Motzer, Memorial Sloan Kettering Cancer Center

Adjuvant Treatment Options
Bradley McGregor, Dana-Farber Cancer Institute

Strategies for Patients with Non-Clear Cell RCC
Laurence Albiges, Institut Gustave-Roussy

Novel Therapies Outside Immunotherapy
Rana McKay, University of California, San Diego

Novel Immunotherapy Strategies
David Braun, Yale Cancer Center

 

Coffee Break

Session 6: Immunotherapy Advances and Research
Moderated by
Hans Hammers, UT Southwestern Medical Center &
David McDermott, Beth Israel Deaconness

Overview in Development of Immunotherapy for Kidney Cancer
Michael Atkins, Georgetown-Lombardi Comprehensive Cancer Center

Uncovering the Tumor-Immune Microenvironmental Determinants of Immunotherapy Response in Renal Cell Carcinoma Through Ex Vivo Patient-Derived Models
David Braun, Yale School of Medicine

Mechanisms and Predictors of Adoptive Cytokine-Induced Memorylike NK Cell Therapy in Renal Cell Carcinoma
Rizwan Romee, Dana-Farber Cancer Institute

Delineate Tumor-Immune Contexture That Shapes ccRCC Metastatic Progression and Response to Immunotherapy
Srinivas Malladi, University of Texas Southwestern Medical Center

Consortium Clinical Trial and the Mechanisms and Preclinical Research
Jonathan Powell, Calico Labs

Lunch and Networking

Session 7: Oral Abstract Presentations
Moderated by
Rana McKay, University of California, San Diego &
Yuksel Urun, Ankara University School of Medicine

SPEAKERS TO BE DETERMINED

Afternoon Break

Session 8: Rapid Abstract Presentations
Moderated by
Sumanta Pal, City of Hope Comprehensive Cancer Center &
Evita Sadimin, City of Hope Comprehensive Cancer Center

SPEAKERS TO BE DETERMINED

Special Session: Biotech Showcase
Moderated by
Tom Powles, Barts Cancer Centre & Hans Hammers, UT Southwestern Medical Center

KCRS24 Closing
Bryan Lewis, KidneyCAN President

Thank You to the KCRS24 Partners & Sponsors

The Kidney Cancer Research Summit is funded through contributions from both grassroots donors and industry partners. We thank the generous partners and sponsors who support us in our mission to accelerate cures for kidney cancer.

Sustaining Partners

Research Sponsors

Community Sponsor

Friends of KidneyCAN